Pfizer new antiviral
June 22, 2026
32 min
Full
364 of 364
June 22, 2026
Pfizer new antiviral
0:00 / 32:47
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Dr John Campbell Episodes Around June 22, 2026
Episode 364 of 364 — walk the feed in the order it was published.
32:47This episodePfizer new antiviral
Summary
Protectors from hospitalisation, the story so far.
Oral meds than can be prescribed from home with onset of symptoms
Molnupiravir, approved by MHRA
https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra
The antiviral was found to be safe and effective following a stringent review of the available evidence.
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
Public domain data, Merck press release
$ 700 per 5-day course
Under 50% reduction in deuteriation
Effect of early treatment with fluvoxamine
Together Trial group
Public domain data, Peer reviewed trial in the Lancet
https://clinicaltrials.gov/ct2/show/NCT04727424
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext
Adults with a risk factor
$4 for a 10-day course
32% protection against hospitalization
32% protection against death
Fluvoxamine is approved by the Food and Drug Administration as an antidepressant
Doctors already can prescribe it off-label — using their clinical judgment
https://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/?
https://bnf.nice.org.uk/drug/fluvoxamine-maleate.html
https://www.togethertrial.com
Ivermectin, Together trial results not yet released
PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY
https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
Public domain data, Pfizer press release
PAXLOVID™ (PF-07321332; ritonavir)
Found to reduce the risk of hospitalization or death by 89%
Compared to placebo in non-hospitalized high-risk adults with COVID-19
Through Day 28
PAXLOVID group
No deaths
Placebo group
10 deaths
Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible
Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)
Randomized, double-blind study of non-hospitalized adult patients with COVID-19,